ADVERTISEMENT

Gland Pharma Q3 Results Review - Pricing Pressure Enters Into Injectables: Axis Securities

Gland Pharma reported a weak set of results in Q3 FY23 with consolidated revenue declining by 11.8% Y0Y.

<div class="paragraphs"><p>Injectables manufactured by Gland Pharma Ltd. (Source: Company website)</p></div>
Injectables manufactured by Gland Pharma Ltd. (Source: Company website)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit